Get the Stockscreener App
1.38
0.73%
0.010
Pasithea Therapeutics Corp Stock (KTTA) Forecast
The Pasithea Therapeutics Corp (KTTA) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.4098, representing a -70.30% decrease from the current price of $1.38. The highest analyst price target is $0.3888, and the lowest is $0.4308.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month KTTA Price Target
Average 0.3327
(-75.89% Downside)
Is Pasithea Therapeutics Corp (KTTA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 52.78 | Neutral |
| STOCH(9,6) | 26.03 | Neutral |
| STOCHRSI(14) | 59.64 | Neutral |
| MACD(12,26) | 0.00478 | Buy |
| ADX(14) | 22.53 | Neutral |
| William %R | -73.85 | Neutral |
| CCI(14) | 60.75 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.303
Buy
|
1.3182
Buy
|
| MA20 |
1.2905
Buy
|
1.2957
Buy
|
| MA50 |
1.2876
Buy
|
1.4768
Sell
|
| MA100 |
2.0003
Sell
|
2.0422
Sell
|
| MA200 |
3.2993
Sell
|
3.1945
Sell
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, KTTA could be considered a Neutral, with 17 technical analysis indicators signaling 6 Buy signals, 5 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on KTTA, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 52.78 indicates that KTTA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 26.03 indicates that KTTA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 59.64 indicates that KTTA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 22.53 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 60.75 indicates that KTTA is still overbought but not to an extreme extent.
Long-term KTTA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Pasithea Therapeutics Corp financial reports and earnings history, Pasithea Therapeutics Corp (KTTA) stock could reach $4.5563 by 2030, $14.36 by 2040 and $25.09 by 2050. See the projected annual prices until 2050 of the Pasithea Therapeutics Corp stock below:
- Pasithea Therapeutics Corp (KTTA) is expected to reach an average price of $8.9501 in 2035, with a high prediction of $8.9015 and a low estimate of $8.9624. This indicates an $548.56% rise from the last recorded price of $1.38.
- Pasithea Therapeutics Corp (KTTA) stock is projected to chart a bullish course in 2040, with an average price target of $13.57, representing an $883.03% surge from its current level. The forecast ranges from a conservative $13.64 to a sky-high $14.36.
- Our analysts predict Pasithea Therapeutics Corp (KTTA) to jump 1,300% by 2045, soaring from $19.52 to an average price of $19.32, potentially reaching $19.54. While $19.52 is the low estimate, the potential upside is significant.
- Pasithea Therapeutics Corp (KTTA) stock is expected to climb by 2050, reaching an average of $24.15, a $1,650% jump from its current level. However, a wide range of estimates exists, with high and low targets of $25.09 and $23.83, respectively, highlighting the market's uncertainty.
Pasithea Therapeutics Corp Stock (KTTA) Year by Year Forecast
Pasithea Therapeutics Corp Stock (KTTA) Price Forecast for 2025
Pasithea Therapeutics Corp Stock (KTTA) is expected to reach an average price of $0.5108 in 2025, with a high prediction of $0.6587 and a low estimate of $0.3629. This indicates an -62.99% fall from the last recorded price of $1.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $0.5853 | $0.4308 | $0.3888 | -57.59% |
| June, 2025 | $0.5709 | $0.6361 | $0.6587 | -58.63% |
| July, 2025 | $0.6001 | $0.5247 | $0.4875 | -56.51% |
| August, 2025 | $0.6151 | $0.616 | $0.5936 | -55.42% |
| September, 2025 | $0.6245 | $0.6158 | $0.6045 | -54.74% |
| October, 2025 | $0.6233 | $0.6139 | $0.5867 | -54.84% |
| November, 2025 | $0.532 | $0.532 | $0.5684 | -61.45% |
| December, 2025 | $0.3029 | $0.3629 | $0.4142 | -78.05% |
Pasithea Therapeutics Corp Stock (KTTA) Price Forecast for 2026
The predicted value for Pasithea Therapeutics Corp (KTTA) in 2026 is set at an average of $1.7676. Estimates vary from a peak of $3.5284 to a trough of $0.00675, indicating an +28.09% surge from the present price of $1.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.1214 | $0.1415 | $0.2673 | -91.20% |
| February, 2026 | $0.0552 | $0.0683 | $0.0888 | -96.00% |
| March, 2026 | $0.0612 | $0.00675 | $0.051 | -95.56% |
| April, 2026 | $0.0499 | $0.0836 | $0.0479 | -96.38% |
| May, 2026 | $0.0587 | $0.0587 | $0.0564 | -95.75% |
| June, 2026 | $0.0106 | $0.0396 | $0.0426 | -99.24% |
| July, 2026 | $2.378 | $0.0134 | $2.238 | +72.32% |
| August, 2026 | $2.4498 | $2.4467 | $2.3311 | +77.52% |
| September, 2026 | $2.6372 | $2.4941 | $2.3929 | +91.10% |
| October, 2026 | $2.5847 | $1.616 | $3.5284 | +87.30% |
| November, 2026 | $3.3065 | $3.1218 | $3.1365 | +139.60% |
| December, 2026 | $3.3539 | $3.4039 | $3.3052 | +143.04% |
Pasithea Therapeutics Corp Stock (KTTA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Pasithea Therapeutics Corp (KTTA) is $2.5944, with a high forecast of $3.377 and a low forecast of $1.8118. This indicates an +88.00% increase from the last price of $1.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.3813 | $3.3883 | $3.377 | +145.03% |
| February, 2027 | $2.9188 | $2.9888 | $3.2157 | +111.51% |
| March, 2027 | $2.9206 | $2.8975 | $2.8619 | +111.64% |
| April, 2027 | $3.043 | $2.8949 | $2.9608 | +120.51% |
| May, 2027 | $2.7398 | $2.7498 | $2.9868 | +98.54% |
| June, 2027 | $2.5473 | $2.6573 | $2.6942 | +84.58% |
| July, 2027 | $2.2347 | $2.3647 | $2.4216 | +61.93% |
| August, 2027 | $2.1465 | $2.1765 | $2.1121 | +55.54% |
| September, 2027 | $1.8939 | $2.0338 | $1.9652 | +37.24% |
| October, 2027 | $1.9314 | $1.9326 | $1.8914 | +39.95% |
| November, 2027 | $1.8232 | $1.8763 | $1.8757 | +32.11% |
| December, 2027 | $1.9306 | $1.8118 | $1.7875 | +39.90% |
Pasithea Therapeutics Corp Stock (KTTA) Price Forecast for 2028
In 2028, Pasithea Therapeutics Corp (KTTA) is projected to reach an average price of $1.2456, with a high projection of $1.9683 and a low estimate of $0.5229. This indicates an -9.74% fall from the last price of $1.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.8271 | $1.8923 | $1.9683 | +32.40% |
| February, 2028 | $1.785 | $1.7275 | $1.7188 | +29.35% |
| March, 2028 | $1.7288 | $1.7433 | $1.7226 | +25.27% |
| April, 2028 | $1.7097 | $1.7116 | $1.6716 | +23.89% |
| May, 2028 | $1.5765 | $1.5965 | $1.6291 | +14.24% |
| June, 2028 | $1.414 | $1.414 | $1.5039 | +2.46% |
| July, 2028 | $1.0958 | $1.1558 | $1.2783 | -20.60% |
| August, 2028 | $0.843 | $0.8631 | $1.0401 | -38.91% |
| September, 2028 | $0.7055 | $0.7186 | $0.7926 | -48.87% |
| October, 2028 | $0.6224 | $0.5901 | $0.655 | -54.90% |
| November, 2028 | $0.5399 | $0.5799 | $0.5913 | -60.88% |
| December, 2028 | $0.4773 | $0.5229 | $0.4929 | -65.41% |
Pasithea Therapeutics Corp Stock (KTTA) Price Forecast for 2029
The 2029 price forecast for Pasithea Therapeutics Corp Stock (KTTA) is $2.9398 on average, with a high prediction of $5.6128 and a low estimate of $0.2668. This represents an +113.03% increase from the previous price of $1.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.3401 | $0.3691 | $0.393 | -75.35% |
| February, 2029 | $5.042 | $0.2668 | $4.902 | +265.36% |
| March, 2029 | $4.8082 | $5.0751 | $4.9416 | +248.42% |
| April, 2029 | $5.1409 | $5.0511 | $4.9143 | +272.53% |
| May, 2029 | $5.017 | $4.0839 | $4.307 | +263.55% |
| June, 2029 | $5.5932 | $5.5006 | $5.2531 | +305.30% |
| July, 2029 | $5.6259 | $5.6759 | $5.6128 | +307.67% |
| August, 2029 | $5.582 | $5.6378 | $5.5955 | +304.49% |
| September, 2029 | $5.0482 | $5.1182 | $5.3986 | +265.81% |
| October, 2029 | $4.9609 | $4.9709 | $4.9413 | +259.48% |
| November, 2029 | $5.012 | $4.9174 | $4.9298 | +263.19% |
| December, 2029 | $4.6197 | $4.6297 | $4.9236 | +234.76% |
Pasithea Therapeutics Corp Stock (KTTA) Price Forecast for 2030
Pasithea Therapeutics Corp Stock (KTTA) is expected to reach an average price of $3.553 in 2030, with a high forecast of $4.5563 and a low forecast of $2.5498. This signifies an +157.47% surge from the last price of $1.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $4.3559 | $4.4659 | $4.5563 | +215.64% |
| February, 2030 | $3.972 | $4.102 | $4.2124 | +187.83% |
| March, 2030 | $3.8482 | $3.8862 | $3.7782 | +178.86% |
| April, 2030 | $3.4709 | $3.6108 | $3.7547 | +151.51% |
| May, 2030 | $3.4371 | $3.4571 | $3.3971 | +149.06% |
| June, 2030 | $3.255 | $3.3107 | $3.3636 | +135.87% |
| July, 2030 | $3.2759 | $3.1894 | $3.2198 | +137.39% |
| August, 2030 | $3.1255 | $3.2221 | $3.278 | +126.48% |
| September, 2030 | $2.97 | $2.9302 | $2.9711 | +115.22% |
| October, 2030 | $2.8424 | $2.8569 | $2.8893 | +105.97% |
| November, 2030 | $2.7521 | $2.7671 | $2.7675 | +99.43% |
| December, 2030 | $2.5298 | $2.5498 | $2.6536 | +83.32% |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):